Advances in Fertility Control and the Treatment of Sterility: The Proceedings of a Special Symposium Held at the Xith World Congress on Fertility and

ISBN-13: 9789401159326 / Angielski / Miękka / 2012 / 117 str.

R. Rolland

Opis

Since human prolactin was isolated and characterized 13 years ago, the study of the control of prolactin secretion has been intensive. Hyperprolactinaemia is the most commonly identifiable hypothal- amic pituitary disorder1,2. The dominant inhibitory nature of hypo- thalamic control of prolactin secretion may be the reason that hyperprolactinaemia is such a common condition. During the PClst decade two separate therapeutic approaches to the management of hyperprolactinaemia have been introduced: transsphenoidal selec- tive pituitary microsurgery and medical therapy to suppress prolactin secretion with orally active long-acting dopamine agonist drugs. Small prolactin-secreting tumours are treated extremely satisfactorily both with medical and with surgical therapy, both in terms of lower- ing serum prolactin levels to normal and in restoring gonadal func- tion. However, for the larger tumours, either where the tumour is invasive or the pretreatment serum prolactin level is greater than 1 250ngml- the results of surgery are poor in terms of restoring to normal circulating prolactin levels and gonadal functionJ-s. We now discuss the medical management of hyperprolactinaemia, potential problems during pregnancy and the management of large prolactin- secreting pituitary tumours.

Spis treści

1 Pre-treatment evaluation of ovarian infertility.- 2 Hyperprolactinaemic infertility: some considerations on medical management.- 3 Lisuride — a new drug for treatment of hyperprolactinaemic disorders.- 4 Benefits and risks of hormonal contraception — interpretation.- 5 Towards safer oral contraception.- 6 The influence of the triphasic pill and a desogestrel-containing combination pill on some physical, biochemical and hormonal parameters: a preliminary report.- 7 Clinical comparison between a monophasic preparation and a triphasic preparation.- 8 Comparative study of lipid metabolism and endocrine function in women receiving levonorgestrel- and desogestrel-containing oral contraceptives.- 9 Androgenic properties of progestogens used in oral contraceptives.- 10 Effect of oral contraceptives upon serum lipoprotein pattern in healthy women.- 11 Carbohydrate metabolism alterations with monophasic, sequential and triphasic oral contraceptives containing ethinyloestradiol plus levonogestrel or desogestrel.